drugset

drugset / Trial / NCT06086613

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

NCT06086613 ↗

Phase 1 Completed 72 enrolled Angitia Incorporated Limited

RandomizedSequentialDouble-blindTreatment

Summary

To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.

Timeline

Start: 2023-10-03
Primary completion: 2024-10-17
Completion: 2024-10-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AGA2115	Unknown	—	Subcutaneous

Indications